explore -WSS

explore

author：hotspot 2025-10-01 11:00:08 - browse：34

Doctor Monica Bertagnolli, a white woman with short hair and bangs, sits at a hearing behind her name tag — coverage from STAT — National Institutes of Health Director Monica Bertagnolli testifies during her Senate HELP Committee confirmation hearing on Oct. 18 in Washington. Kevin Dietsch/Getty Images

WASHINGTON — The new National Institutes of Health director, Monica Bertagnolli, said it’s a “failure” that enrollment in government-funded clinical trials has lagged behind those funded by the pharmaceutical industry.

“If you just look at the number of patients who go on government-funded trials, it’s been completely flat over the last decade,” she said at a meeting of the advocacy group Friends of Cancer Research. “If you go and look at the number of people who go on pharma-sponsored trials, it’s just this commitment and this increase.”

A Johns Hopkins University study published in 2015 showed that the pharmaceutical industry funds six times more clinical trials than the government. Industry-sponsored trials increased 43% from 2006 to 2014, while newly registered NIH-funded trials decreased 24% over the same period.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： A daunting task: navigating dual Medicare, Medicaid eligibility

WSS

Microsoft launches AI tool for clinical documentation through Epic

Dana Farber says 6 studies to be retracted and 31 corrected

Medicare bonuses could stop drug shortages under Senate plan

CRISPR pioneers react to Casgevy, first gene

Inaction leaves children at risk from dangerous chemotherapy drug

David Sabatini, ex

explore

explore

hotspot

In age of alternative facts, a scholarly course on calling out crap

To bolster infectious disease surveillance, genomics powerhouses team up

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

High breast density mammograms need follow

Trump demands the U.S. pay no more for drugs than other countries … again

Gain of function research would be limited under House proposal

Apple is now the first public company to be valued at $3 trillion

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

Alkermes shareholders re

Head of FDA's diagnostics center, who led through Covid, retires

knowledge

Morphosys mixed study results for blood cancer drug

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

What causes osteoarthritis? Researchers study link to brain protein

Dana Farber says 6 studies to be retracted and 31 corrected

World's first CRISPR

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

hotspot

focus

focus

focus